As a firm responsible for managing global portfolios for pharmaceutical companies, we closely follow and seek to stay abreast of developments regarding patentability in various jurisdictions. We recently reviewed the Unified...more
8/22/2024
/ Amgen v Sanofi ,
Corporate Counsel ,
Disclosure ,
Enablement Inquiries ,
Inventions ,
Patent Invalidity ,
Pharmaceutical Patents ,
Prior Art ,
Priority Patent Claims ,
Sanofi-Aventis ,
SCOTUS ,
Unified Patent Court
Following the U.S. Supreme Court’s invalidation of a counterpart U.S. patent in the same family for lack of enablement (21-757 Amgen Inc. v. Sanofi (05/18/23) (supremecourt.gov)), the UPC has now rendered a decision on its...more